Pfizer Introduces Zylexis, The UK’s First And Only Equine Immunomodulator
12 years ago
14884 views
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator* licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen that boosts a horse’s immune system to reduce the effects of infectious respiratory disease1,2 – bridging the gap between potential and performance. It acts by stimulating the horse’s non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse’s adaptive immune system can develop a pathogen-specific response.3-5
Research has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 Furthermore, no local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, commented: “Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It’s a very welcome addition to the medicine box of UK vets.”
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
*Licensed to reduce clinical signs of equine respiratory disease associated with over-crowding and stress
For further information contact your Pfizer Account Manager.
Fachinger V, et al. Evidence for a parapox ovis virus-associated superantigen. Eur J Immunol 2000; 30: 2962–2971.Zylexis Summary of Product Characteristics, April 2012.Mayr A. Development of a non-immunising, paraspecific vaccine from attenuated pox viruses: a new type of vaccine. New Microbiol 2003; 26; 7–12.Weber O, et al. Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 2003; 84(Pt 7): 1843–1852.Friebe A, et al. Immunomodulatory effects of inactivated parapoxvirus ovis (Orf Virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells. J Virol 2004; 78(17): 9400–9411.Pfizer Study No. Equine 1–98.Ziebell KL, et al. The use of Baypamun N in crowding associated infectious respiratory disease: efficacy of Baypamun N (freeze dried product) in 4 –10 month old horses. Zentralbl Veterinarmed B 1997; 44(9): 529– 536Field Safety Trial Report. Nov. 20, 2000, Pfizer Inc.14884 views
Posted
16th August, 2012 18h58
More from
- IVC Evidensia assembles expert team to run new £10m referral hospital
- Home delivery service can increase pet health plan sign-ups by 25%
- Research reveals vital clues to help fight anthelmintic resistance
- Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
- Bake sale at Leicestershire vet practice for good cause